Fundación MEDINA and WeLab Barcelona

Fundación MEDINA and WeLab Barcelona

Fundación Medina and WeLab Barcelona have signed a collaboration agreement that allows combining experience and resources for the discovery and development of new therapies.

MEDINA, an international reference Centre in the discovery of new natural products, will provide access to its unique HTS technology platforms and chemistry expertise to support innovative drug discovery programs.

Welab Barcelona, the platform of drug discovery and development integrated in Leitat Technological Centre, will provide access to its comprehensive capabilities, expertise, and in-depth knowledge to support pharmaceutical R&D.

Nota de prensa (Castelllano)

Nota de premsa (Català)

Dear colleagues, collaborators, and friends,

After more than 30 years of shared endeavours, in which we have grown personally and professionally, and with our emotions on the surface, we announce the closure of our company. We have travelled together through ups and downs, celebrated successes and overcome challenges as a team.

We extend our deepest gratitude to each of you for your dedication, passion, and commitment to a shared goal: discovering new treatments for the benefit and well-being of patients.

As we bid farewell, let’s cherish the memories we’ve created, the bonds we’ve formed, and the impact we’ve made together. Though our paths may diverge, the spirit of collaboration and camaraderie that defines our community will always endure.

We leave proud of the work accomplished and thank you for being an integral part of our journey, wishing you success in all your future challenges.

With heartfelt appreciation,

Welab’s team

We are proud to announce that Welab is partner of this new EU funded project.

In collaboration with 12 partners from 6 countries, Welab Barcelona is establishing the Antivirus Pandemic Preparedness EuropeAn pLatform (APPEAL), a European research initiative aimed at enhancing preparedness for future pandemics. This EU funded collaboration will establish a comprehensive program for the development of broad-spectrum antiviral drugs within a five year time frame ensuring drug affordability and accessibility to low income countries.
Link to the press release: